CD6
T-cell differentiation antigen CD6
As of the edition of 20 October 2026, CD6 (T-cell differentiation antigen CD6, UniProt P30203) has 1 drug tested at it and 3 companies on the list, 3 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P30203
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- In more than one place
- Solved structures
- 1
- Disease areas
- Immune system; Lungs and airways; Skin and connective tissue; Infections; Bones, joints and muscles; Nervous system; Pregnancy and women's health; Urinary and reproductive
- Registered trials of its drugs
- 10
Drugs at this target
| Status | Count |
|---|---|
| Stopped | 1 |
| Total | 1 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Itolizumab | Stopped | Phase 3 | none listed |
1 of 1 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Total on the list | 3 |
| Company | Route |
|---|---|
| Equillium | Route A |
| Biocon | Route A |
| Biotech Pharmaceutical | Route A |
The other 0 companies at CD6
In the product3 companies in all; 0 are not named here, and no score is.
See the 3 companies at CD6, ranked, with the facts behind eachRequest access. Nothing is shown until you do.